Johnson & Johnson (JNJ)

JNJ on New York Consolidated

100.12USD
3 Jun 2015
Change (% chg)

$0.14 (+0.14%)
Prev Close
$99.98
Open
$100.32
Day's High
$100.38
Day's Low
$99.84
Volume
648,415
Avg. Vol
7,839,873
52-wk High
$109.49
52-wk Low
$95.10

JNJ

Chart for JNJ

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $277,249.09
Shares Outstanding(Mil.): 2,773.04
Dividend: 0.75
Yield (%): 3.00

Financials

  JNJ Industry Sector
P/E (TTM): 17.90 36.69 38.84
EPS (TTM): 5.59 -- --
ROI: 14.86 17.28 16.53
ROE: 22.04 18.14 17.62
Search Stocks

U.S. economy contracts in first quarter; dollar hurts corporate profits

WASHINGTON - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly. | Video

29 May 2015

WRAPUP 4-U.S. economy contracts in Q1; dollar hurts corporate profits

WASHINGTON, May 29 - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly.

29 May 2015

FBI probing what J&J knew about uterine surgery device: WSJ

- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

27 May 2015

UPDATE 1-FBI probing what J&J knew about uterine surgery device - WSJ

May 27 - The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

27 May 2015

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

UPDATE 2-J&J to submit at least 10 new drugs for approval by 2019

May 20 - U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

20 May 2015

CORRECTED-UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19)

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

20 May 2015

Achillion partners with J&J to develop hepatitis C drugs

- Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

19 May 2015

UPDATE 1-Achillion partners with J&J to develop hep C drugs

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

19 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks